Innovating.works Conecta tu I+D

Mostrando 1 al 20 de 170 resultados

DeepGenetics: Deep genetics to study and uncover ‘hidden’ biology STICHTING HET NEDERLANDS KANKER INSTITUUTANTONI VAN LEEUWENHOEK ZIEKENHUIS tramitó un HORIZON EUROPE: ERC-2023-ADG Human genes are organized in complex networks, to produce thousands of proteins to perform a myriad of functions. Whereas we have detailed m...
2024-09-01 - 2029-08-31 | Financiado

pepTalks: Causes and consequences of aberrant mRNA translation in cancer STICHTING HET NEDERLANDS KANKER INSTITUUTANTONI VAN LEEUWENHOEK ZIEKENHUIS tramitó un HORIZON EUROPE: ERC-2023-ADG Shortages in amino acids are weapons in the warfare between tumor cells and tumor-infiltrating lymphocytes. Tumor cells enhance or inhibit t...
2024-09-01 - 2029-08-31 | Financiado

Adaptmet: Deconstructing adaptive evolution of metastasis Adaptmet aims to develop an advanced training program encompassing the multifaceted aspects of metastasis adaptation mechanisms, intending t...
2024-07-05 - 2029-02-28 | Financiado

PARADOX: Paradoxical activation of oncogenic signaling as a cancer treatment strategy. STICHTING HET NEDERLANDS KANKER INSTITUUTANTONI VAN LEEUWENHOEK ZIEKENHUIS tramitó un HORIZON EUROPE: ERC-2023-ADG Cancer cell homeostasis requires a balance between activated oncogenic pathways driving tumorigenesis and engagement of stress-response prog...
2024-07-01 - 2029-06-30 | Financiado

INFRAPLUS: Enhancing and Evolving INFRAFRONTIER Disease Modelling Capacity to Enable Breakthrough Research STICHTING HET NEDERLANDS KANKER INSTITUUTANTONI VAN LEEUWENHOEK ZIEKENHUIS participó en un HORIZON EUROPE: HORIZON-INFRA-2023-DEV-01 In response to the HORIZON-INFRA-2023-DEV-01-03 call, INFRAPLUS aims to expand INFRAFRONTIER's capacity for human disease modelling, refine...
2024-06-20 - 2027-05-31 | Financiado

PARADOX: Paradoxical activation of oncogenic signaling as a cancer treatment strategy. STICHTING HET NEDERLANDS KANKER INSTITUUTANTONI VAN LEEUWENHOEK ZIEKENHUIS tramitó un HORIZON EUROPE: ERC-2023-ADG Cancer cell homeostasis requires a balance between activated oncogenic pathways driving tumorigenesis and engagement of stress-response prog...
2024-05-31 - 2029-06-30 | Financiado

DeepGenetics: Deep genetics to study and uncover hidden biology STICHTING HET NEDERLANDS KANKER INSTITUUTANTONI VAN LEEUWENHOEK ZIEKENHUIS tramitó un HORIZON EUROPE: ERC-2023-ADG Human genes are organized in complex networks, to produce thousands of proteins to perform a myriad of functions. Whereas we have detailed m...
2024-05-31 - 2029-08-31 | Financiado

pepTalks: Causes and consequences of aberrant mRNA translation in cancer STICHTING HET NEDERLANDS KANKER INSTITUUTANTONI VAN LEEUWENHOEK ZIEKENHUIS tramitó un HORIZON EUROPE: ERC-2023-ADG Shortages in amino acids are weapons in the warfare between tumor cells and tumor-infiltrating lymphocytes. Tumor cells enhance or inhibit t...
2024-05-24 - 2029-08-31 | Financiado

HoloSurge: Multimodal 3D Holographic tool and real time Guidance System with point of care diagnostics for surg... Perioperative care is an intricate process that encompasses 1) preoperative evaluation, surgical planning and preparation; 2) intraoperative...
2023-12-07 - 2027-12-31 | Financiado

PragmaTIL: Pragmatic approach to Adoptive Cell Therapy (ACT) using Tumor Infiltrating Lymphocytes (TIL) in sele... STICHTING HET NEDERLANDS KANKER INSTITUUTANTONI VAN LEEUWENHOEK ZIEKENHUIS participó en un HORIZON EUROPE: HORIZON-MISS-2022-CANCER-01 The PragmaTIL trial aims to optimize treatment of cancer patients with Tumour-Infiltrating Lymphocytes Adoptive Cell Therapy (TIL-ACT) and s...
2023-04-28 - 2028-03-31 | Financiado

Fragment-Screen: From fragments to high affinity binders interfacing integrated structural biology medicinal chemist... STICHTING HET NEDERLANDS KANKER INSTITUUTANTONI VAN LEEUWENHOEK ZIEKENHUIS participó en un HORIZON EUROPE: HORIZON-INFRA-2022-TECH-01 Fragment-Screen will develop innovative instrumentation, workflows and experimental and computational methodologies for fragment-based drug...
2022-12-13 - 2026-01-31 | Financiado

Maxima Butterfly: From Caterpillar to BUTTERFLY: supporting transformation of DCs in a paediatric oncology network STICHTING HET NEDERLANDS KANKER INSTITUUTANTONI VAN LEEUWENHOEK ZIEKENHUIS participó en un HORIZON EUROPE: HORIZON-MSCA-2021-COFUND-01 Every year, around 600 children in the Netherlands get cancer and one in four children dies from this illness. More than ten years ago, a gr...
2022-10-10 - 2027-12-31 | Financiado

ReverT: Reversing T cell dysfunction in cancer by multimodal genetic screening STICHTING HET NEDERLANDS KANKER INSTITUUTANTONI VAN LEEUWENHOEK ZIEKENHUIS tramitó un HORIZON EUROPE: ERC-2021-ADG T cell dysfunction is a key problem in cancer, enabling not only tumorigenesis but also causing resistance to immunotherapy. Induction of im...
2022-10-01 - 2027-09-30 | Financiado

STRONG-AYA: THE STRONG-AYA INITIATIVE: IMPROVING THE FUTURE OF YOUNG ADULTS WITH CANCER STICHTING HET NEDERLANDS KANKER INSTITUUTANTONI VAN LEEUWENHOEK ZIEKENHUIS tramitó un HORIZON EUROPE: HORIZON-HLTH-2021-CARE-05 STRONG-AYA is a new, interdisciplinary, multi-stakeholder European network to improve healthcare services, research and outcomes for Adolesc...
2022-10-01 - 2027-09-30 | Financiado

RE_LOCATE: Location, location, location: the (re-)positioning of regulatory elements in the mammalian genome. STICHTING HET NEDERLANDS KANKER INSTITUUTANTONI VAN LEEUWENHOEK ZIEKENHUIS tramitó un HORIZON EUROPE: ERC-2021-ADG "In mammalian genomes, the enhancers (E) that control a promoter (P) are often scattered over tens to hundreds of kb, and frequently interdi...
2022-09-01 - 2027-08-31 | Financiado

STEPUPIORS: TWINNING FOR A EUROPEAN CONSORTIUM OF RECTAL CANCER RESEARCH INSTITUTIONS THROUGH STEPPING UP SCIENT... STICHTING HET NEDERLANDS KANKER INSTITUUTANTONI VAN LEEUWENHOEK ZIEKENHUIS participó en un HORIZON EUROPE: HORIZON-WIDERA-2021-ACCESS-03 "Neoadjuvant chemoradiotherapy (CRT) is the gold standard in locally advanced rectal cancer (LARC), but the response is not uniform among pa...
2022-07-14 - 2025-09-30 | Financiado

OncoFetal_Ploidy: Understanding aneuploidy tolerance in cancer by studying early embryogenesis STICHTING HET NEDERLANDS KANKER INSTITUUTANTONI VAN LEEUWENHOEK ZIEKENHUIS tramitó un HORIZON EUROPE: HORIZON-MSCA-2021-PF-01 Can we study complex cancer biology by using a more predictable and structured model of embryogenesis? Many of the hallmarks of cancer biolo...
2022-07-01 - 2024-11-30 | Financiado

NKI AVL